Prevent preclinical drug development program: preclinical efficacy and intermediate biomarkers task order title: sulforaphane for the prevention of malignant mesothelioma
Active Awarded Last action
- Contract number
- 75N91023F00003
- Awardee
-
The Institute For Cancer Research UEI FF1XVJMDYVR1 Part of Temple University-Of The Commonwealth System Of Higher Education
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,199,274
Award facts
- Opportunity
-
- TORFP2023E01 Solicitation number
- Contract value 100% obligated
- $1,199,274.00 Current and potential, with all options
- Completion date 87% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Philadelphia, PA 19111, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Original award | $1,199,274 |
About this award
The National Cancer Institute issued a delivery order to The Institute For Cancer Research on May 3, 2023, under the PREVENT Preclinical Drug Development Program IDC for preclinical efficacy and biomarker studies on sulforaphane for malignant mesothelioma prevention, with a ceiling value of $1,199,274 and an ultimate completion date of May 2, 2027.
PREVENT is a National Cancer Institute multiple-award IDC supporting structured preclinical drug and vaccine development across three technical pools: Preclinical Efficacy and Biomarkers, Preclinical Services for Product Development and Manufacturing, and Preclinical Toxicology and Pharmacology Testing. The Institute For Cancer Research, a non-profit subsidiary of Temple University, performs work in Philadelphia, PA on a firm fixed-price basis.
Labor activity shows 0.6 FTEs and 1,220 contractor hours invoiced in FY2023 at $81.11 per hour, scaling to 1.5 FTEs and 3,078 contractor hours in FY2024 at $128.58 per hour. The awardee self-performed all reported work with no subcontractors.
Quick answers
Who was awarded contract 75N91023F00003?
75N91023F00003 was awarded to The Institute For Cancer Research by National Cancer Institute (National Institutes of Health) on May 3, 2023.
How much is contract 75N91023F00003 worth?
The government has obligated $1,199,274 on 75N91023F00003.
Is contract 75N91023F00003 an order under another contract?
Yes. 75N91023F00003 is a delivery order under 75N91019D00022, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91023F00003 competed?
The extent of competition for 75N91023F00003 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award